Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nonsteroidal Anti-Androgens

Known as: Anti-Androgens, Nonsteroidal, AntiAndrogens, Nonsteroidal, Nonsteroidal Anti Androgens 
Nonsteroidal agents which block the action or downregulate the synthesis of ANDROGENS.
National Institutes of Health

Related topics

Related topics

5 relations
In Bloodagonistsaspects of radiation effectschemical synthesis
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
A Second Act for Antiandrogens Men with advanced prostate cancer are often treated with antiandrogens; drugs that inhibit the… Expand
Highly Cited
2008
Highly Cited
2008
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
PURPOSE Large meta-analyses have documented that maximum androgen blockade with nonsteroidal antiandrogens for advanced prostate… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2003
Highly Cited
2003
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
PURPOSE Androgen deprivation is implicated in reducing neoangiogenesis in prostate cancer (PCA). Androgens regulate the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
UV filters with antagonistic action at androgen receptors in the MDA-kb2 cell transcriptional-activation assay.
The fact that certain ultraviolet (UV) filters used in cosmetics display estrogenic activity prompted us to study potential… Expand
Highly Cited
1997
Highly Cited
1997
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic…
OBJECTIVES To evaluate the short- and long-term effects of neoadjuvant hormonal treatment in locally confined prostate cancer… Expand
  • table I
  • table II
Highly Cited
1997
Highly Cited
1997
Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
OBJECTIVES To assess the survival benefit of maximum androgen blockade (MAB) using nonsteroidal antiandrogens (NSAAs) through… Expand
Highly Cited
1995
Highly Cited
1995
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
We report a dramatic decrease in prostate specific antigen in response to the discontinuation of megestrol acetate in a patient… Expand
Highly Cited
1993
Highly Cited
1993
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Structural changes of the androgen receptor (AR) may contribute to the development of resistance to endocrine therapy in… Expand
Highly Cited
1991
Highly Cited
1991
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen… Expand
Highly Cited
1981
Highly Cited
1981
Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens.
Abstract The competition of a series of steroidal androgens and steroidal and non-steroidal antiandrogens, with [3H… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE